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Abstract: Carbonic anhydrase inhibitors (CAIs), such as dorzolamide (DZA), are used as
anti-glaucoma drugs to lower intraocular pressure, but it has been found that some of these drugs act
as vasodilators of retinal arteries. The exact mechanism behind the vasodilatory effect is not yet clear.
Here we have addressed the issue by using small vessel myography to examine the effect of CAIs of
the sulfonamide and coumarin type on the wall tension in isolated segments of porcine retinal arteries.
Vessels were pre-contracted by the prostaglandin analog U-46619, and CAIs with varying affinity for
five different carbonic anhydrase (CA) isoenzymes found in human tissue tested. We found that all
compounds tested cause a vasodilation of pre-contracted retinal arteries, but with varying efficacy,
as indicated by the calculated mean EC50 of each compound, ranging from 4.12 µM to 0.86 mM. All
compounds had a lower mean EC50 compared to DZA. The dilation induced by benzolamide (BZA)
and DZA was additive, suggesting that they may act on separate mechanisms. No clear pattern in
efficacy and affinity for CA isoenzymes could be discerned from the results, although Compound 5,
with a low affinity for all isoenzymes except the human (h) CA isoform IV, had the greatest potency,
with the lowest EC50 and inducing the most rapid and profound dilation of the vessels. The results
suggest that more than one isozyme of CA is involved in mediating its role in controlling vascular
tone in retinal arteries, with a probable crucial role played by the membrane-bound isoform CA IV.
Keywords: carbonic anhydrase; vasodilation; vascular tone
1. Introduction
Carbonic anhydrases (CAs; EC 4.2.1.1) are a class of ubiquitous zinc enzymes that are present
in a wide variety of tissues in living organisms [1]. Their main function is to reversibly catalyze a
basic physiological reaction, namely, the conversion of CO2 to bicarbonate and protons. These proteins
are encoded by seven evolutionarily unrelated gene families, and one of these, the α-Cas, are present
in vertebrates including mammals, but also in bacteria, algae, protozoans, fungi and green plants.
About 16 α-CAs or CA-related proteins have been described in mammals [1–3], and these are known
to have different tissue distribution, subcellular localization and catalytic activity, and it is unlikely
that this family of CAs will be found to be larger. Among the catalytically active human expressed
isoenzymes, five are expressed in the cytosol (I-III, VII and XIII), two are mitochondrial (VA and VB)
one is secreted (VI), and four are transmembrane proteins (IV, IX, XII and XIV) [1–3]. Development of
carbonic anhydrase inhibitors (CAIs) as therapeutic agents must take into consideration the fact that
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their effects on non-target isoenzymes must be minimal. CAIs have been developed for the treatment
of a variety of diseases, since CA plays a role in several important physiological functions, such as
transport of CO2 and bicarbonate, lipogenesis, gluconeogenesis, calcification, bone resorption, and
tumorigenicity, to name a few [3]. The CA isoenzymes involved in these physiological processes are,
therefore, potential therapeutic targets for treating various disorders such as cancer, epilepsy, glaucoma,
acute mountain sickness, pain and osteoporosis by inhibition of target CA isozymes [4–7]. The use of
CAIs for treatment of glaucoma has been well established for decades, as such drugs lower intraocular
pressure (IOP) [8–11]. However, topical DRZ eye drops were found to not only lower IOP but also to
increase blood flow in the retinal vasculature and optic nerve region in patients [12,13]. Similar effects
of systemic applications of CAIs were found on the retinal vasculature and optic nerve oxygenation in
pig eyes [14,15]. These findings suggest that as a glaucoma treatment, CAIs may have dual beneficial
effects on the viability of optic nerve fibers in glaucoma, that is, they cause an increase in blood flow
and oxygenation in the optic nerve region of patients, in addition to lowering their elevated IOP.
Subsequently, it was found that the CAIs used for glaucoma treatment have a direct vasodilatory effect
on pre-contracted retinal arteries isolated from both bovine [16] and porcine [17,18] eyes, measured by
small vessel myography. The exact physiological mechanism behind the vasodilatory effect of CAIs
remains unclear, although several factors, such as alterations in pH and CO2 levels, or processes other
than CA inhibition, have been proposed [18,19]. In this study, we report the effects of new compounds
with CA inhibitory properties, but different affinities for both cytosolic and transmembrane CA
isoenzymes on the wall tension of isolated segments of porcine retinal arteries, measured by small
vessel myography. The purpose of this study was to ascertain if one or more of the CA isozymes are
involved in controlling vascular tone in these vessels, and thus shed further light on the mechanisms
involved, and its location in cells.
2. Results
For the purposes of this study, we considered two main CA inhibitory moieties: i) The classical
sulfonamide-based CAIs which include the clinically used BZA 1, DZA 2 and the synthesized
benzenesulfonamide derivative 3; and ii) the coumarin based CAIs 4–6 (Figure 1). The synthesis
of compounds 3–6 was accomplished according to the procedures reported in the literature [20–25].
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The compounds in Figure 1 were all tested in vitro for their inhibition potencies against the
human expressed CA isoforms considered relevant in controlling vascular tone (i.e. I, II, IV, IX and
XII). The results are reported in Table 1, in comparison with the standard sulfonamide inhibitor
acetazolamide (AAZ).
Table 1. Inhibition data of human CA isoforms I, II, IV, IX and XII with compounds 1–6 and AAZ by a
stopped flow CO2 hydrase assay [26].
KI (nM) *
Cmp hCA I hCA II hCA IV hCA IX hCAXII
1 (BZA) 15.0 [1] 9.0 12.0 45.0 3.5 [2]
2 (DZA) >10000 [3] 9.0 8500 52.0 3.5
3 4014.0 5.8 370.8 55.7 9.1
4 >10000 >10000 69.2 4747.6 56.4
5 >10000 [4] >10000 [4] 76.4 1350.0 [4] 730.0 [4]
6 >10000 >10000 59.7 474.3 44.5
AAZ 250 12 74 25.8 5.7
* Mean from 3 different assays, by a stopped flow technique (errors were in the range of ± 5%–10% of the
reported values).
The data reported in Table 1 show that the BZA was a potent inhibitor against all the hCA
isoforms considered here, with KIs in the low nanomolar concentrations. The only exception was
the tumor associated isoform, IX, which was inhibited from BZA at a concentration of 45 nM. The
anti-glaucoma CAI, DZA 2, showed close matching inhibition potencies to 1, the only differences
being the ineffectiveness on hCA isoforms I and IV (KI values of >10000 and 8500 nM, respectively).
The synthesized sulfonamide compound 3 showed a better inhibition profile when compared to the
clinically used BZA and DZA, being particularly potent in inhibiting hCA II and XII, with KI values
of 5.8 and 9.1 nM, respectively. Higher KI values were obtained for the isoform hCA IX (55.7 nM),
followed by the membrane associated hCA IV (370.8 nM), and then by the ubiquitous hCA I (4014 nM).
A different inhibition profile was obtained for the coumarin based scaffolds 4–6. In agreement with
the coumarins inhibition data reported in the literature [24,25], compounds 4–6 were ineffective in
inhibiting the cytosolic hCA I and II (KIs >10000) and maintained inhibition potencies against the
membrane associated ones. The 6-substituted alkyne derivative 4 showed comparable KIs values
for hCAs IV and XII, comprised in the medium nanomolar range (69.2 and 56.4 nM, respectively),
whereas the tumor associated isoform IX was inhibited at a micromolar concentration (KI of 4747.6 nM).
Interestingly, the 7-substituted alkyne derivative 5 retained the inhibition potency against the hCA
IV with comparable KI values to its regioisomer compound 4 (KI of 76.4 nM). Additionally, 5 was
3.5-fold more potent than 4 in inhibiting hCA IX, but was 12.9 times less effective against hCA XII
(KI 730.0 nM). The 4-methyl-7-alkyl substituted coumarin 6 showed an inhibition profile close to 4, but
was by far the most potent in inhibiting all the membrane associated isoforms, that is, hCA IV, IX and
XII (KIs of 59.7, 474.3 and 44.5 respectively).
The sulfonamide CAI BZA 1 (Figure 1), in consideration of its enhanced acidic properties at
physiological pH, has for a long time been assumed to act primarily on CAs on the extracellular side
of cell membranes [27]. Such a chemical feature, however, does not significantly alter the ability of
BZA to cross bio-membranes, as it has been demonstrated to accumulate in the cytoplasm of red blood
cells incubating with the drug for more than 15 min [6]. We therefore examined the effect of BZA on
the wall tension of porcine retinal arteries pre-contracted with 10−6 M of U-46619, and a representative
experiment is shown in Figure 2A.
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the U-46619 induced vasoconstriction. In another experiment illustrated in Figure 2B, when 10−3 M 
DZA was added to the bath after the U-46619 reached a peak, it exerted a 33% vasodilation. When 
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Figure 2. The effects of U-46619, BZA and DZA on wall tension in porcine retinal arteries. A:
Continuous myography recording of wall tension in one artery. The vertical arrow on the left indicates
the time point when 10−6 M U-46619 was added to the bath. The wall tension then increases and
reaches a peak, and 10−3 M BZA was added at the time indicated by the right vertical arrow. Note
the rapid vasodilation induced by BZA to the b s line level. B: Myography re ording from another
rt ry. After vasoconstriction induced by U-46619 reached a pe k, 10−3 M DZA w s dded at the time
in icated by the middle arrow. The left vertical arrow indicates an addition of 10−3 M BZA. Note the
additional dilation induced by BZA. C: Mean concentration-response curves for the dilatory effects
of BZA (filled circles) and a (open triangles), expressed as a percentage of the maximum contraction
induced by U-46619. Symbols represent the mean ± standard error of the mean (SEM) dilation at each
concentration. D: The mean ± SEM dilation induced by BZA and DZA in response to a single dose
of 10−3 M added to the bathing solution, as a percentage of the maximum contraction induced by
U-46619. An asterix (*) above bars indicates statistically significant vasodilation (p < 0.002)
Fig re 2A shows a continuous recording of wall tension of the arterial wall (in mN/mm of wall
length) after normalization of contractile tension in the vessel segment. U-46619 was added to the
tissue bath containing the retinal artery at the point indicated by the vertical arrow on the left. The wall
tension increased from 0.4 mN/mm at the baseline to a peak force of about 1.75 mN/mm after addition
of U-46619, which is comparable to the mean change in wall tension induced by the drug in healthy
porcine retinal arterioles under the present experimental conditions. When wall tension had reached a
peak after the addition of 10−6 M U-46619, 10−3 M BZA was added to the bath at the point indicated
by the vertical arrow on t righ in Figur 2A, producing an lmost complete inhibition of the U-46619
induced vasoconstriction. In another experiment illustrated in Figure 2B, when 10−3 M DZA was
added to the bath after the U-46619 reached a peak, it exerte a 33% vasodilation. When the dilation
had reached a steady level, 10−3 M BZA was added to the bathing solution, and it immediately induced
an additional dilation, to a final 100% of the maximum contraction. The concentration dependency of
both compounds was examined on five different vessel segments, as shown in Figure 2C. The mean
EC50 of BZA was calculated by best fit to the concentration-response curves as 8.43 × 10−5 M, and the
mean EC50 of DZA as 8.6 × 10−4 M, a statistically significant difference (Two-tailed t-test, p < 0.001).
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Thus, BZA is a more potent vasodilator of porcine retinal arteries than DZA, as further indicated
by Figure 2D, which shows the mean vasodilation induced by the compounds with a 10−3 M dose,
expressed as a percentage of the vasoconstriction evoked by U-46619. At this concentration, BZA
caused a significant mean dilatation of 78.4% ± 8.5% (n = 7, p < 0.002), while the mean dilation induced
by 10−3 M DZA was 69.7% ± 5.7% (n = 7, p < 0.002). The difference in the vasodilation induced by the
two compounds at 10−3 M was not significant (p = 0.398).
The effect of CAIs listed as Compounds 3 and 4 in Table 1 on the wall tension of retinal artery
segments pre-contracted with U-46619 were then examined and prepared as described in Section 4.1
on chemistry. The two compounds vary greatly in their affinity for the isoenzymes hCA II and hCA
IX, as indicated in Table 1. Figure 3A shows a continuous recording of wall tension in a retinal
artery segment.
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added to the bath at the point indicated by the vertical arrow. When the vasoconstriction that 
followed had reached a peak value of 2.4 mN/mm, a single dose of 10−3 M of compound 3 was added 
to the bathing medium. Compound 3 induced a rapid vasodilation, which in this experiment was 
91% of the maximum constriction. Figure 3B presents a recording from another retinal artery 
Figure 3. The effects of U-46619 and compounds 3 and 4 on retinal arterial wall tension. A: Continuous
recording of wall tension. First, 10−6 M U-46619 was added to t e bath, and when the vasoconstriction
reached a p ak in the experiment shown, a single dose of 10−3 M of compound 3 was added at the
point indicated by the right vertical arrow. B: Co t nuous recording of wall ension from another vessel.
At the peak of vasoconstriction induced by U-46619, a ose of 10−3 M of compound 4 was added at
the point indicated by the right arrow. C: Mean concentration-response curves for the dilatory effects
of compounds 3 (filled circles) and 4 (open triangles), expressed as a percentage of U-46619 induced
maximum contraction. D: The mean dilation induced by compounds 3 and 4 in response to a single
dose of 10−3 M added to the bathing solution, as a percentage of the maximum contraction induced
by U-46619. An asterix (*) above a bar indicates statistically significant vasodilation (p < 0.01 and
p < 0.002).
With a baseline wall tension stable at 0.6 mN/mm in Figure 3A, a dose of 10−6 M U-46619 was
added to the bath at the point indicated by the vertical arrow. When the vasoconstriction that followed
had reached a peak value of 2.4 mN/mm, a single dose of 10−3 M of compound 3 w s added to
the bathing medium. Compound 3 induced a rapid vasodilation, which in this experiment was 91%
of the maximum constriction. Figure 3B presents a recording from another retinal artery segment,
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with the mean wall tension baseline stable at about 0.38 mN/mm. A dose of 10−6 M U-46619 was
added and induced a peak constriction of 1.63 mN/mm. A single dose of 10−3 M of compound 4
was then added, and it induced a two-phased dilation in this vessel, initially a very fast one to about
0.66 mN/mm, followed by a slower phase that reached a wall tension of about 0.36 mN/mm, or an
overall vasodilation of 101% in this particular experiment. The concentration dependency of both
compounds 3 and 4 was examined on four different vessel segments, as shown in Figure 3C. The
mean EC50 of compound 3 was calculated as 1.88 × 10−4 M, and the mean EC50 of compound 4 as
1.34 × 10−4 M, with a statistically significant difference between those two means (Two-tailed t-test,
p < 0.02). Figure 3D compares the mean vasodilation induced by the two compounds with a 10−3
M dose, expressed as percentage of the vasoconstriction evoked by U-46619. Compound 3 at 10−3
M induced a significant mean dilatation of 102.2% ± 3.7% (n = 5, p < 0.01), while the mean dilation
induced by 10−3 M of compound 4 was 98.8% ± 6.1% (n = 4, p < 0.002). The difference in vasodilation
induced by the two compounds at 10−3 M was not significant (p = 0.343).
The effect of two new coumarin CAIs listed as compounds 5 and 6 in Table 1—both with low
affinity for human CA isoenzymes I and II—on arterial wall tension was then tested in the same
manner as for compounds 3 and 4, and the results are illustrated in Figure 4. An experiment examining
the effect of a single dose of 10−3 M of compound 5 is shown in Figure 4A.
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Figure 4. The effects of U-46619, and compounds 5 and 6 on retinal arterial wall tension. A: Continuous
recording of wall tension. After adding 10−6 M U-46619 to the bath, and when constriction had
reached a peak, a single dose of 10−3 M of compound 5 was added, as indicated by the right vertical
arrow. B: Recording of wall tension fr m a second vessel. At the peak of vasoconstriction i uced
by U-46619, a dose of 10−3 M of compound 6 was added at he point indicat d by the right arrow.
C: Mean concentration-response curves for the dilatory effects of compounds 5 (filled circles) and 6
(open triangles), expressed as a percentage of U-46619 induced maximum contraction. D: The mean
dilation induced by compounds 5 and 6 in response to a single dose of 10−3 M added to the bathing
solution, as a percentage of the maximum contraction induced by U-46619. Asterix (*) above the bars
indicate statistically significant vasodilation (p < 0.001 and p < 0.002).
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In Figure 4A, with the baseline wall tension stable at 1.54 mN/mm, 10−6 M U-46619 was added
to the bath at the point indicated by the vertical arrow. When the vasoconstriction induced by the drug
had reached a peak value of 3.38 mN/mm, 10−3 M of compound 5 was added to the bath at the time
indicated by the right vertical arrow. Compound 5 evoked a rapid vasodilation, which reached a level
that was lower than the baseline wall tension before addition of U-46619, or 0.77 mN/mm, that is, the
vasodilation in the experiment illustrated reached 140% of the maximum contraction of the vessel at
peak. Figure 4B presents a recording from another retinal artery segment, with the mean wall tension
baseline reaching a stable level of 0.95 mN/mm. A dose of 10−6 M U-46619 was added and induced a
peak constriction of 2.21 mN/mm. A single dose of 10−3 M compound 6 was then added and induced
a slow vasodilation, which was 96.8% of the maximum contraction of the vessel. The concentration
dependency of compounds 5 and 6 was examined on four different vessel segments, as shown in
Figure 4C. The mean EC50 of compound 5 was calculated in the same manner as 4.12 × 10−6 M, and
the mean EC50 of compound 6 as 1.01 × 10−4 M, a statistically significant difference (Two-tailed t-test,
p < 0.001). The mean vasodilation induced by the two compounds with a 10−3 M dose, expressed
as a percentage of the vasoconstriction evoked by U-46619, is illustrated in Figure 4D. At 10−3 M,
compound 5 induced a significant mean dilation of 116.5% ± 1.7% (n = 4, p < 0.001), while the mean
dilation induced by 10−3 M of compound 6 was 99.5% ± 1.2% (n = 4, p < 0.002). The difference in the
vasodilation induced by the two compounds at 10−3 M was significant (Two tailed t-test, p < 0.001).
3. Discussion
The present study shows for the first time that BZA causes a vasodilation in isolated porcine
retinal arterioles, which is significantly more profound than that induced by DZA, as found previously
by some studies [16,18]. We are not aware of any previous study showing a direct vasodilatory effect
on isolated vessels by this compound. The results support the suggestion that BZA is a membrane
permeable CAI, as has been shown in isolated red blood cells [6], although it has so far been generally
(and erroneously) assumed to be an impermeant CAI and has been used as such [28–31]. The dilation
induced by BZA may be due to inhibition of one or more of either cytosolic- or membrane-bound
CA isoenzymes, or both. The dilating effect of the compound is additive to that induced by DZA,
suggesting that the vasodilation induced by these compounds may involve separate mechanisms to
some extent. BZA has been proposed as a putative treatment for acute mountain sickness [7] and
myocardial ischemia [32], primarily due to its effect on acidity, but the potent effect on vascular tone
demonstrated here raises the possibility of other putative therapeutic uses. On a cellular level, BZA has
been found to inhibit calcium currents mediated by voltage-sensitive calcium channels expressed on
the membranes of HEK293 cells [33], and low-threshold calcium currents in hippocampal pyramidal
cells [34]. It is not clear if these effects are related to the vasodilatory effects of BZA and other CAIs
shown here, but it has been shown that charybdotoxin, the selective blocker of calcium activated
potassium channels (KCa), blocks vasodilation of isolated mesenteric arteries induced by CAIs [35]. The
present results also suggest that more than one isoenzyme of CA is likely to be involved in mediating
the vasodilation, and thus in maintaining vascular tone. The physiological mechanisms involved, aside
from CA inhibition, are still unclear, although several hypotheses have been formulated. It has been
found that changes in pH or CO2 levels induced by CA inhibition are not the mechanisms responsible
for the vasodilation, since vasodilation can still be induced by CAIs at normal pH, but acidosis does
appear to reduce the effect to some extent [16,18]. Intracellular acidosis in vascular smooth muscle
cells is increased by DZA, but that increase is not related to relaxation [19]. Hypercapnia, however, has
no effect on the vasodilatory effect of CAIs [18]. The perivascular tissue plays a role, since vasodilation
is significantly reduced in isolated porcine retinal arterioles, with perivascular tissue removed [17].
There is evidence that nitric oxide (NO), presumably released from the endothelium, is involved in the
vasodilatory effect of CAI, since it is reduced in the presence of nitric oxide synthase (NOS) inhibitor
L-NAME or guanylyl cyclase inhibitor ODQ [19,36]. It has also been argued that inhibition of CA is not
necessarily the mechanism responsible for vasodilatory effects of the inhibitors, due to the relatively
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high concentrations needed [18,37], but we have shown here that some CAIs, such as compound 5 in
the present study, induce vasodilation at a low concentration, with a low, micromolar EC50. In this
study, we have examined the vasodilatory effects of a series of sulfonamide/coumarin CAIs with
varying structure and affinity for different isoenzymes of CA, and find that all of them, regardless of
selectivity, induced vasodilation in pre-contracted retinal arteries, but with some differences in potency,
which may be related to their relative affinity for the CA isozymes. Further studies of the effect of
CAIs with different selectivity for cytosolic versus membrane bound isozymes, and greater specificity
for individual isozymes are needed to clarify the role of carbonic anhydrase in controlling vascular
tone in retinal arteries.
4. Materials and Methods
4.1. Chemistry
Anhydrous solvents and all reagents were purchased from Sigma-Aldrich (Milan, Italy), Alfa
Aesar (Milan, Italy) and TCI (Milan, Italy). All reactions involving air- or moisture-sensitive compounds
were performed under a nitrogen atmosphere using dried glassware and syringes techniques to transfer
solutions. Nuclear magnetic resonance (1H-NMR, 13C-NMR) spectra were recorded using a Bruker
Avance III 400 MHz spectrometer in DMSO-d6. Chemical shifts are reported in parts per million
(ppm) and the coupling constants (J) are expressed in Hertz (Hz). Splitting patterns are designated as
follows: s, singlet; d, doublet; t, triplet; q, quadruplet; m, multiplet; brs, broad singlet; dd, double of
doublets. The assignment of exchangeable protons (OH and NH) was confirmed by the addition of
D2O. Analytical thin-layer chromatography (TLC) was carried out on Merck silica gel F-254 plates.
Melting points (m.p.) were carried out in open capillary tubes and are uncorrected. The solvents
used in MS measures were acetone, acetonitrile (Chromasolv grade), purchased from Sigma–Aldrich
(Milan, Italy), and mQ water 18 MX, obtained from Millipore’s Simplicity system (Milan, Italy). The
mass spectra were obtained using a Varian 1200L triple quadrupole system (Palo Alto, CA, USA)
equipped by Electrospray Source (ESI), operating in both positive and negative ions. Stock solutions
of analytes were prepared in acetone at 1.0 mg mL−1 and stored at 4 ◦C. Working solutions of each
analyte were freshly prepared by diluting stock solutions in a mixture of mQ H2O/ACN 1:1 (v/v) up to
a concentration of 1.0 µg mL−1. The mass spectra of each analyte were acquired by introducing via
syringe pump at 10 µL min−1 its working solution. Raw data were collected and processed by Varian
Workstation Vers. 6.8 software.
4.2. Carbonic Anhydrase Inhibition
An Applied Photophysics stopped-flow instrument was used for assaying the CA catalyzed CO2
hydration activity [1]. Phenol red (at a concentration of 0.2 mM) was used as an indicator, working
at an absorbance maximum of 557 nm, with 20 mMHepes (pH 7.5) as buffer, and 20 mM Na2SO4 for
maintaining constant ionic strength, following the initial rates of CA-catalyzed CO2 hydration reaction
for a period of 10–100 s. CO2 concentrations ranged from 1.7 to 17 mM for the determination of the
kinetic parameters and inhibition constants. For each inhibitor, at least six traces of the initial 5%–10%
of the reaction were used to determine the initial velocity. The uncatalyzed rates were determined in
the same manner and subtracted from the total observed rates. Stock solutions of inhibitor (0.1 mM)
were prepared in distilled and deionized water, and dilutions up to 0.01 nM were carried out with
the assay buffer. Inhibitor and enzyme solutions were preincubated together for 15 min at room
temperature prior to assay, to allow for the formation of the E-I complex. The inhibition constants
were obtained by non-linear least-squares methods using PRISM 3 and the Cheng–Prusoff equation, as
reported earlier [24,25]; these represent the mean from at least three different determinations. All CA
isoforms were recombinant ones obtained in-house, as reported previously [24,25].
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4.3. Myography Preparation
Changes in the wall tension of short segments (<2 mm) of porcine retinal arterioles were examined
with a small vessel myography system. Pig eyes were obtained from a local abattoir. The pigs were
anesthetized with CO2 and put down by exsanguination. All procedures involving animals adhered to
the appropriate local and international laws and relevant ethical rules. Only one eye was obtained from
each animal for the experiments. Eyes were placed in a 4 ◦C oxygenated physiological saline solution
(PSS) and transported to the laboratory as quickly as possible (within 30 min). The composition of PSS
used for both transport of the eyes and as the extracellular bathing solution for myography recordings
from isolated retinal arterioles was as follows (in mM): 112.6 NaCl; 5.91 KCl; 24.9 NaHCO3; 1.19 MgCl2;
1.18 NaH2PO4; 2.0 CaCl2; 11.5 glucose, all dissolved in double distilled water. The PSS was oxygenated
by a mixture of 95% O2 and 5% CO2 with pH maintained at 7.4.
The eyes were bisected with a razor blade at the equator and the anterior segment removed.
The vitreous was then removed from the posterior segment and replaced with 4 ◦C oxygenated PSS.
The posterior segment containing the optic disk was then placed under a stereoscope. The arteries
were identified based on their smaller diameter compared to the adjacent venule, and the color of
the blood inside the vessels. A straight arteriolar segment was then selected as close to the optic disc
as possible, and an approximately 2 mm long segment was dissected, with retinal tissue extending
approximately 1 mm on either side of the vessel. Dissected segments of porcine retinal arteries were
mounted in a DMT630MA wire myograph system (DMT A/S, Aarhus, Denmark) for measurement of
contractile activity. The myograph system consisted of four separate tissue baths, so that four vessel
segments could be examined simultaneously, with a volume of up to 10 ml, and in each bath there is
a force transducer to measure tension to a thin tungsten wire, placed in the lumen of a vessel. The
recording chambers can be automatically emptied of PSS with suction and quickly refilled again with
an automatic buffer filler system (625FS, DMT A/S, Aarhus, Denmark). The vessel segments were
placed in between two metal jaws in the chamber, with two screws on the jaws to attach a tungsten
wire to it. The arteries were mounted on two tungsten wires with a diameter of 25 µm, guided by a
stereo microscope. Two incisions were made through the retinal artery and adjacent retina in situ, and
one tungsten wire guided first through the lumen and along the vessel from one incision to the other.
Incisions on both sides of the arterial segment through the retina were then made, and the retinal
vessel segment, with the wire inside the lumen, transferred to the myography recording chamber. The
wire was first tied with the screws on both ends to the jaw attached to the micrometer. A second wire
was then guided through the lumen along the top of the first wire, and then attached to the jaw of
the force transducer with the screws there. The exact length of the vessel segment, once placed in the
myography system, was measured by taking a photograph of it through the stereoscope, and then
converting the vessel length in pixels into millimeters. The heating unit of the DMT630MA system
was then turned on and set to a stable temperature of 37 ◦C, monitored by a thermal probe inserted
into the bathing medium.
4.4. Myography Procedure
The wall tension of the vessel segment was continuously recorded with LabChart Pro
(ADInstruments, Oxford, UK). Once the temperature in the bathing medium had reached 37 ◦C,
the preparation was left to stabilize for 30 min and the normalization of wall tension was carried out,
taking into account the measured length of the vessel. The normalization was done so that results
from vessel segments with different diameters were comparable. The procedure involves increasing
the vessel diameter by separating the wires inside the lumen by the micrometer in fixed steps, and
at each step determine the passive tension of the vessel wall (which corresponds to a transmural
pressure between about 0–70 mmHg). The diameter-tension relationship in this is exponential, and
was extrapolated from the measurements using the DMT Normalization module of LabChart Pro.
The intercept between the exponential function of measured diameter-tension and a straight line
was calculated, based on the Laplace equation (wall tension = transmural pressure × radius) with
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transmural pressure in the equation set to 70 mmHg. By adjusting the built-in micrometer in each
chamber of the myograph system, the jaws were set so that they were placed at about 94% of the
intercept length, as calculated by the DMT Normalization module. The wall tension at that level is at
maximum tension (i.e., the optimal passive stretch of the smooth muscle cells of the vessel wall).
After normalization the vessel segments were pre-contracted with the thromboxane A2 analogue
U-46619 (9,11-dideoxy-9 α,11α methanoepoxy prostaglandin F2α) (Cayman Chemicals Inc., Tallinn,
Estonia), which was dissolved in demineralized water to a stock solution of 10−3 M. The stock solution
was added to the myography tissue bath to reach a final concentration of 10−6 M. Experiments were
discarded if the peak increase in wall tension induced by 10−6 M U-46619 was less than 0.5 mN/mm.
Once the vasoconstriction induced by U-46619 reached a peak, the CAI to be tested was added to the
bathing medium. Stock solutions of all carbonic anhydrase inhibitors were made at 0.1 M concentration,
dissolved in DMSO, and then diluted to the desired concentration. A dose of 10−3 M of all the CAIs
examined in this study was in each case tested first, as a point of reference to ascertain if the compound
had any effect on wall tension of the arteries.
Concentration-response curves were obtained by adding the lowest concentration tested, in most
cases 10−6 M or lower, to the bathing medium and then adding the next step (e.g., 2 × 10−6 M) when
the change in wall tension induced by the previous concentration had reached a steady level.
4.5. Data Analysis
The myography recording traces were copied from LabChart Pro to SigmaPlot 13 (Systat Software
Inc, San Jose, CA, USA) for graphic analysis and presentation, as well as all other graphics. Statistical
analysis was performed using Systat (Systat Software Inc, San Jose, CA, USA). The estimation of EC50
from normalized concentration-response curves was calculated by best fit, using GraphPad Prism 8
(GraphPad Software Inc., San Diego, CA, USA). The results are expressed as means ± SEM.
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